8-K: Inspire Medical Systems Reports Strong Q4, Full Year 2025

Inspire Medical Systems announced robust financial results for Q4 and full year 2025, driven by the successful Inspire V system launch, despite facing reimbursement coding challenges for 2026.

Summary

• Inspire Medical Systems achieved strong financial performance in Q4 and full year 2025, with revenue growth of 12% and 14% respectively.
• The company successfully launched its Inspire V system, which has shown positive patient outcomes and improvements in therapy delivery.
• FDA approval was received for 3.0T MRI compatibility for the Inspire V system.
• A clarification regarding the coding for the Inspire V procedure will transition it to CPT code 64582 with a -52 modifier, which is expected to negatively impact physician fees.
• The full year 2026 revenue outlook has been revised to a range of $950 million to $1.0 billion, representing 4% to 10% annual growth, reflecting the estimated impact of coding uncertainty.
• A proposal will be put forth at the 2026 Annual Meeting of stockholders to amend the Certificate of Incorporation to declassify the Board of Directors and provide for annual election of directors.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed filing. While Q4 and full-year 2025 financial results were strong, the revised 2026 outlook and the negative impact of reimbursement coding changes introduce significant uncertainty and temper enthusiasm for future growth.

Positives

• Fourth quarter 2025 revenue increased 12% to $269.1 million compared to the prior year.
• Full year 2025 revenue increased 14% to $912.0 million compared to the prior year.
• Gross margin improved to 86.6% in Q4 2025 (up 160 bps) and 85.4% for full year 2025 (up 70 bps).
• Net income per diluted share was $4.66 in Q4 2025 and $4.89 for full year 2025, significantly boosted by a tax benefit.
• Adjusted net income per diluted share was $1.65 in Q4 2025 and $2.42 for full year 2025.
• Operating cash flow was $52.5 million in Q4 2025 and $117.0 million for full year 2025.
• The Inspire V system launch was successful, with clinical insights validating positive patient outcomes and improvements in therapy delivery.
• Received FDA approval for 3.0T MRI compatibility for the Inspire V system.
• Completed $175 million in share repurchases during 2025.
• Over 125,000 patients have received Inspire therapy to date, with high reported satisfaction rates (91% say Inspire is better than CPAP, 93% would recommend).

Negatives

• The company is disappointed with the coding clarification for the Inspire V procedure, which transitions it to CPT code 64582 with a -52 modifier, expected to impact physician fees.
• The full year 2026 revenue outlook was revised downwards to $950 million to $1.0 billion (4% to 10% growth), reflecting estimated impact from coding uncertainty and related physician reimbursement rates.
• Cash, cash equivalents, and investments decreased by $111.9 million to $404.6 million as of December 31, 2025, compared to December 31, 2024.
• Operating expenses increased 9% in Q4 2025 and $84.1 million for the full year, driven by investments in commercial infrastructure, patient marketing, and medical education.

Risks

• Uncertainty or changes in billing codes for Inspire therapy could impact reimbursement rates and physician usage.
• Financial results may fluctuate significantly and may not fully reflect the underlying performance of the business.
• The company has a history of operating losses and is dependent on its Inspire therapy for revenues.
• Challenges exist in achieving and maintaining adequate and clear levels of coverage or reimbursement for Inspire therapy or any future products.
• Competition from other companies, technologies, and pharmaceuticals in the industry poses a risk.
• Involvement in current or future legal disputes or regulatory proceedings, including a civil investigative demand from the Department of Justice and patent infringement suits with Nyxoah S.A. and Nyxoah, Inc.
• The ability to expand indications and develop and commercialize additional products and enhancements to Inspire therapy is a factor.
• Future results of operations, financial position, research and development costs, capital requirements, and needs for additional financing are uncertain.
• The ability to accurately forecast customer demand for Inspire therapy and manage inventory is a risk.
• Dependence on third-party suppliers, vendors, and contract manufacturers could impact operations.
• Consolidation in the healthcare industry may affect the business.
• The ability to expand, manage, and maintain the direct sales and marketing organization, and to market and sell Inspire therapy in markets outside of the U.S., is a challenge.
• Risks related to product liability claims and warranty claims exist.
• The ability to address quality issues that may arise with Inspire therapy is important.
• The impact of glucagon-like peptide 1 (GLP-1) class of drugs on demand for Inspire therapy is a potential risk.
• Risks related to information technology and cybersecurity are present.
• The ability to commercialize or obtain regulatory approvals for Inspire therapy, or the effect of delays in commercializing or obtaining regulatory approvals, is a concern.
• FDA or other U.S. or foreign regulatory actions affecting the company or the healthcare industry generally could have an impact.

Future Outlook

Inspire Medical Systems revised its full year 2026 revenue outlook to a range of $950 million to $1.0 billion, representing 4% to 10% annual growth. This revised range reflects the estimated impact on the first quarter due to coding uncertainty and the range of outcomes from applying CPT code 64582 with a -52 modifier and related physician reimbursement rates. Additionally, the company expects an annual adjusted operating margin in the range of 6% to 8%, net income per diluted share between $1.23 and $1.81, and adjusted net income per diluted share between $1.85 and $2.35. The outlook assumes an effective tax rate of approximately 44% to 49% and an adjusted effective tax rate of 26% to 28%, estimated weighted average diluted shares outstanding of approximately 29.4 million, and capital expenditures between $45 million to $50 million.

Management Comments

• "We are very excited with the strong finish to 2025. The team made excellent progress with the Inspire V launch, with clinical insights from the early phase of commercial adoption continuing to validate positive patient outcomes and improvements in therapy delivery." Tim Herbert, Chairman and CEO.
• "Despite the dynamic reimbursement landscape, our strong fourth quarter execution positions us well as we enter 2026." Tim Herbert, Chairman and CEO.
• "While we are disappointed with this result [coding clarification], this clarification provides direction for us going forward, and we will work with payers, including the MACs, government agencies, commercial payers and physician societies to attempt to minimize the impact to the physician fee from this change." Tim Herbert, Chairman and CEO.
• "Additionally, we are seeking a long-term solution, namely the creation of a separate CPT code that would support appropriate reimbursement for the Inspire V procedure." Tim Herbert, Chairman and CEO.
• "We remain focused on our commitment to put the patient first and deliver strong patient outcomes. We believe we have a differentiated product, a strong team and that we can drive long-term profitable growth and shareholder value." Tim Herbert, Chairman and CEO.

Industry Context

StockSavvy.ai notes that Inspire Medical Systems operates in the rapidly evolving obstructive sleep apnea (OSA) treatment market, where its neurostimulation therapy offers a minimally invasive alternative to traditional CPAP machines and more invasive surgeries. The company's continued revenue growth and product innovation, such as the Inspire V system and 3.0T MRI compatibility, position it as a leader in this niche. However, the dynamic reimbursement landscape and the potential impact of new drug classes like GLP-1s on OSA demand represent significant industry-wide challenges that could affect all players in the sleep apnea treatment space.

Comparison to Industry Standards

• Inspire therapy demonstrates superior patient experience compared to CPAP, with 91% of patients finding Inspire better, 93% recommending it, and 90% satisfied.
• Inspire patients show a significant reduction in Apnea-Hypopnea Index (AHI) from a median of 33.0 events/hr at baseline to 10.2 events/hr at 12 months, and a reduction in Epworth Sleepiness Scale (ESS) from 11.0 to 6.0.
• Therapy adherence for Inspire patients is high, with an average of 5.7 hours of nightly use at 12 months.
• The Inspire V system's clinical study in Singapore reported 100% successful implants, a 20% reduction in surgical time, and 5.9 hours/night therapy adherence, with no serious device-related adverse events.
• Untreated OSA patients incur approximately $20,000 higher total annual Medicare costs compared to treated patients, highlighting the economic benefit of effective treatments like Inspire therapy.

Corporate Governance

Legal Proceedings

• The company is subject to a civil investigative demand from the Department of Justice.
• The company filed a patent infringement suit against Nyxoah S.A. and its wholly-owned subsidiary, Nyxoah, Inc.
• A patent infringement suit was brought against the company by Nyxoah.

Stakeholder Impact

• Shareholders: Potential for long-term profitable growth and shareholder value, but near-term uncertainty due to reimbursement coding changes and a revised outlook. Share repurchases indicate management's confidence.
• Patients: Continued access to innovative, minimally invasive solutions for obstructive sleep apnea with the Inspire V system and future enhancements. Positive patient outcomes and satisfaction are reported.
• Physicians/Healthcare Centers: Impacted by the coding clarification for the Inspire V procedure, potentially affecting reimbursement rates and administrative burden. The company plans to work with payers to minimize the impact and seek a long-term solution.
• Employees: Continued investments in commercial infrastructure and marketing suggest ongoing growth and opportunities, but also legal expenses related to ongoing disputes.
• Regulatory Authorities: Ongoing engagement with government agencies regarding coding and reimbursement, and compliance with FDA approvals.

Next Steps

• Work with payers, government agencies, commercial payers, and physician societies to minimize the impact of the CPT code change on physician fees.
• Seek a long-term solution for reimbursement, specifically the creation of a separate CPT code that would support appropriate reimbursement for the Inspire V procedure.
• Host a conference call on February 11, 2026, to discuss these results and answer questions.
• Participate in various meetings with investors and analysts in February and March 2026.
• Put forth a proposal at the 2026 Annual Meeting of stockholders to declassify the Board of Directors and provide for annual election of directors.
• Continue development of Inspire VI and VII for auto-activation and future auto-titration.
• Conduct the PREDICTOR study, which is intended to replace DISE (Drug-Induced Sleep Endoscopy) for many patients.

Key Dates

Recommendation

Inspire Medical Systems delivered strong financial results for 2025, demonstrating robust growth and operational efficiency, particularly with the successful launch of the Inspire V system. However, the revised 2026 outlook, specifically the impact of coding uncertainty on physician reimbursement, introduces a notable headwind. While the company is actively pursuing solutions, this issue creates near-term revenue uncertainty. The proposed corporate governance changes are positive for shareholder accountability. Given the strong underlying business performance balanced against the immediate reimbursement challenges and a slight decrease in cash, a 'hold' recommendation is appropriate as investors await clarity on the reimbursement landscape and the company's ability to mitigate its impact.

Keywords

Inspire Medical Systems, INSP, Obstructive Sleep Apnea, OSA, Inspire V, Neurostimulation, Medical Technology, Financial Results, Reimbursement, CPT Code, FDA Approval, Corporate Governance, SleepSync, Patient Outcomes, Medical Device